Re-Vana Therapeutics

Eye
#Boehringer Ingelheim #Collaboration #Ophthalmology #Re-Vana Therapeutics

Boehringer and Re-Vana partner on long-acting ophthalmic therapies

Boehringer Ingelheim and Re-Vana Therapeutics have announced a strategic collaboration and license agreement to develop first-in-class extended-release therapies for eye diseases.  Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients.   Re-Vana’s drug delivery technology is designed to release treatments slowly over… Read More

#Business & Investment #News